According to a recent systematic review and meta-analysis on this topic, mutation rates for BRAF V600E in ameloblastomas range from 33.33% to 92.0% (19); and according to the largest case series reviewed in this study, of the 691 cases evaluated, the immunohistochemical positivity for BRAF V600E ranged from 61.3% to 84% (Table 2). Here, BRAF is linked to ameloblastoma.